10th Mar 2017 14:55
For filings with the FCA include the annex | |||||
For filings with issuer exclude the annex | |||||
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi | |||||
1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii | INTEGRATED DIAGNOSTICS HOLDINGS PLC | ||||
2 Reason for the notification (please tick the appropriate box or boxes): | |||||
An acquisition or disposal of voting rights | X | ||||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached | |||||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments | |||||
An event changing the breakdown of voting rights | |||||
Other (please specify): | |||||
3. Full name of person(s) subject to thenotification obligation: iii | T. Rowe Price Associates, Inc. | ||||
4. Full name of shareholder(s) (if different from 3.):iv | JP Morgan Chase Bank of New York Mellon Bank, N.A. Northern Trust Co. | ||||
5. Date of the transaction and date onwhich the threshold is crossed orreached: v | 08 March 2017 | ||||
6. Date on which issuer notified: | 10 March 2017 | ||||
7. Threshold(s) that is/are crossed orreached: vi, vii | 5% | ||||
8. Notified details: | ||||||||||||||||
A: Voting rights attached to shares viii, ix | ||||||||||||||||
Class/type ofshares if possible usingthe ISIN CODE | Situation previousto the triggeringtransaction | Resulting situation after the triggering transaction | ||||||||||||||
NumberofShares | NumberofVotingRights | Numberof shares | Number of votingrights | % of voting rights x | ||||||||||||
Direct | Direct xi | Indirect xii | Direct | Indirect | ||||||||||||
JE00BV9H9G76 | 7,474,850 | 7,474,850 | 7,570,134 | 7,570,134 | 5.04% | |||||||||||
B: Qualifying Financial Instruments | ||||||||||||||||
Resulting situation after the triggering transaction | ||||||||||||||||
Type of financialinstrument | Expirationdate xiii | Exercise/Conversion Period xiv | Number of votingrights that may beacquired if theinstrument isexercised/ converted. | % of votingrights | ||||||||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi | ||||||||||||||||
Resulting situation after the triggering transaction | ||||||||||||||||
Type of financialinstrument | Exercise price | Expiration date xvii | Exercise/Conversion period xviii | Number of voting rights instrument refers to
| % of voting rights xix, xx
| |||||||||||
| Nominal | Delta | ||||||||||||||
Total (A+B+C) | ||||||||||||||||
Number of voting rights | Percentage of voting rights | |||||||||||||||
7,570,134 | 5.04% | |||||||||||||||
9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi | ||
T. Rowe Price Associates, Inc. (TRPA) serves as investment adviser, with dispositive and voting authority, to various institutional clients that own shares of Integrated Diagnostics Holding Plc., including the T. Rowe Price International Discovery Fund, which owns 5,391,836 shares. Such shares are registered in the following name(s):
Bank of New York Mellon Bank, N.A. - 337,429
JP Morgan Chase - 7,172,393
Northern Trust Co. - 60,312
| ||
Proxy Voting: | ||
10. Name of the proxy holder: | ||
11. Number of voting rights proxy holder will cease to hold: | ||
12. Date on which proxy holder will cease to hold voting rights: | ||
13. Additional information: | ||
14. Contact name: | Gary Greb, Vice President T. Rowe Price Associates, Inc. | |
15. Contact telephone number: | 001 410 345 2527 | |
Related Shares:
Int Diag Hld